Clinical trial NCT05485766: Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer
Official title: Neoadjuvant and Adjuvant Olaparib Plus Pembrolizumab Following Platinum Based Chemotherapy Plus Pembrolizumab for Germline BRCA Mutated Triple Negative Breast Cancer (WJOG14020B/OPERETTA)
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Triple Negative Breast Neoplasms
Triple Negative Breast Cancer
Breast Neoplasms
Breast Cancer
BRCA1 Mutation
BRCA2 Mutation
BRCA Mutation
BRCA-Associated Breast Carcinoma
Keywords: BRCA1 protein
BRCA2 protein
Lead sponsor: Okayama University
Sponsor class: OTHER
Collaborators: name: Merck Sharp & Dohme LLC
First posted: 2022-08-03
Enrollment: 23
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a Phase II, single-arm, open label study to evaluate Olaparib plus Pembrolizumab following platinum-based chemotherapy plus Pembrolizumab as neoadjuvant therapy for germline BRCA (gBRCA) 1/2 mutated triple negative breast cancer (TNBC).

Pembrolizumab in combination with weekly paclitaxel and carboplatin (treatment 1) is followed by Pembrolizumab in combination with Olaparib (treatment 2) in neoadjuvant setting and Pembrolizumab in combination with Olaparib in adjuvant setting will be studied


Eligibility criteria: Inclusion Criteria:

* Male/female subjects who are at least 18 years of age on the day of signing informed consent with histologically confirmed diagnosis of invasive breast cancer
* Have histologically confirmed TNBC, as defined by the most recent ASCO/CAP guidelines.
* Confirmed germline BRCA 1/2 mutated.
* Have previously untreated locally advanced non-metastatic (M0) TNBC defined as the following combined primary tumor (T) and regional lymph node (N) staging per AJCC for breast cancer staging criteria version 7 as assessed by the investigator based on radiological and/or clinical assessment:

  1. T1c, N1-N2
  2. T2, N0-N2
  3. T3, N0-N2
  4. T4a-d, N0-N2
* It has been confirmed that there is no distant metastasis to each organ by the following tests. Chest: Contrast CT or FDG-PET/CT Abdominal: Contract CT\* or FDG-PET/CT Bone: Bone scintigraphy or FDG-PET/CT Brain: In the case of no central nervous system symptoms, examination for brain metastasis is not required.
* The subject (or legally acceptable representative if applicable) provides written informed consent for the trial.
* Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
* Have adequate organ function as defined in the protocol. Specimens must be collected within 10 days prior to the start of study treatment.

Exclusion Criteria:

* Subjects who has a positive urine pregnancy test within 72 hours prior to registration
* Has diagnosed as inflammatory breast cancer.
* Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor .
* Has received a live vaccine or live-attenuated vaccine within 30 days prior to the first dose of study drug.
* Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study intervention.
* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug.
* Has a history of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years.
* Has severe hypersensitivity (≥Grade 3) to pembrolizumab and investigational drugs used in this study and/or any of their excipients.
* Has active autoimmune disease that has required systemic treatment in the past 2 years
* Has a history of (non-infectious) pneumonitis/interstitial lung disease .
* Has an active infection requiring systemic therapy.
* Has a known history of Human Immunodeficiency Virus (HIV) infection.
* Has a known history of Hepatitis B (defined as Hepatitis B surface antigen \[HbsAg\] reactive) or known active Hepatitis C virus (defined as HCV RNA \[qualitative\] is detected) infection.
* Has a known history of active TB (Bacillus Tuberculosis).
* Has a history or current evidence of any condition, therapy, or laboratory abnormality.
* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
* Is pregnant or breastfeeding, or expecting to conceive or father children.
* Has had an allogenic tissue/solid organ transplant.
* Has received pre-treatment with Olaparib or other PARP inhibitors.
* Has significant cardiovascular disease
* Has a resting electrocardiogram (ECG) indicating uncontrolled, potentially reversible cardiac conditions.
* Subject has myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) or with features suggestive of MDS/AML.
* Subject received colony-stimulating factors within 28 days prior to the first dose of study intervention.
* Subject is considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection.
* Is either unable to swallow orally administered medication or has a gastrointestinal disorder affecting absorption.
* Is, in the judgement of the investigator, unlikely to comply with the study procedures, restrictions, and requirements of the study.
* Is currently receiving either strong or moderate inhibitors of cytochrome P450 (CYP)3A4 that cannot be discontinued for the duration of the study.
* Is currently receiving either strong or moderate inducers of CYP3A4 that cannot be discontinued for the duration of the study.

Primary outcomes:
measure: Pathological Complete Response (pCR) Rate (ypT0/TisypN0)
timeFrame: From 27 weeks up to 30 weeks
Secondary outcomes:
measure: Residual Cancer Burden 0/1
timeFrame: From 27 weeks up to 30 weeks
measure: Pathological Complete Response (pCR) Rate (ypT0/is)
timeFrame: From 27 weeks up to 30 weeks
measure: Pathological Complete Response (pCR) Rate (ypT0/Tis ypN0)
timeFrame: From 27 weeks Up to 30 weeks
measure: Three-Year Overall Survival (3-year OS)
timeFrame: Up to 3 years
measure: Three-Year Distant Metastatic Free Survival (3-year DMFS)
timeFrame: Up to 3 years
measure: Three-Year Disease Free Survival (3-year DFS)
timeFrame: Up to 3 years
measure: AEs/SAEs and treatment discontinuation due to AEs/SAEs
timeFrame: Up to 3 years
Other outcomes:
Locations:
city: Gifu
country: Japan
facility: Gifu University Hospital
city: Okayama
country: Japan
facility: Okayama University Hospital
city: Tokyo
country: Japan
facility: St. Luke's International Hospital
Study officials:
affiliation: Assistant Professor, Endocrinological Center, Okayama University Hospital
name: Yuko Takahashi, MD., PhD.
role: PRINCIPAL_INVESTIGATOR
References: